An observational study in Staging and Therapeutic Recommendations, sponsored by French Africa Pediatric Oncology Group. Recruiting at 1 site in France. Open to participants aged 0 Months to 18 Years. Per ClinicalTrials.gov, last updated 2026-03-02.
Sponsored by French Africa Pediatric Oncology Group · Observational
The GFAOP propose a simple and reproducible staging according to clinical, biological and radiological data.
Develop standardized but different therapeutic recommendations based on the availability or lack of radiation therapy in the pilot unites who will adapt these recommendations.
In high-income countries, therapeutic outcomes exceed 90% and therapeutic de-escalation is necessary to reduce mainly the effects of long-term radiotherapy. Within the same country, there are also differences between the therapeutic protocols used in the different centres.
The Experience of Sub-Saharan African Units of the Franco-African Paediatric Oncology Group (GFAOP) in the treatment of pediatric Hodgkin lymphoma in 104 patients was based on chemotherapy alone. The latter was based on COPP/ABV cures without complementary irradiation adapted to the initial stratification and modulated according to the morphological response. Overall survival at 5 years was 82% at 30 months after a median decrease of 17 months.
It seemed appropriate to bring together in a single committee the representatives of the various pilot units in order to standardize the therapeutic protocols in the African countries.
So with this recommendation the GFAOP propose a simple and reproducible staging according to clinical, biological and radiological data.
- Develop standardized but different therapeutic recommendations based on the availability or lack of radiation therapy in the pilot unit.
French Africa Pediatric Oncology Group is the lead sponsor of 6 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All children arriving in one of the participating units :
under 18 years of age at diagnosis and suffering from "classical" Hodgkin's disease according to the WHO classification.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
under 18 years of age at diagnosis
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Descriptive data will be collected to evaluation compliance with the protocol and to evaluate outcome
Patient status
Dead or Alive
Time frame: 24 months
Drugs
The evaluation of the number of children who remain untreated because of lack of acess to chemotherapy
Time frame: 24 months
Started Nov 2022 (actual). Primary completion is estimated for Dec 2028, 73 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
French Africa Pediatric Oncology Group